Eric J. Duncavage, MD

Eric J. Duncavage, MD

Professor, Pathology & Immunology
Division Chief, Genomic and Molecular Pathology
Section Head, Molecular Oncology

 

Division

  • Anatomic & Molecular Pathology

Additional Titles

  • Section Head, Clinical Genomics
  • Section Head, MOTEL

Education

  • Hematopathology Fellow: University of Utah/ARUP lab, Salt Lake City, UT (2009-2010)
  • Molecular Genetic Pathology Fellow: Washington University, St. Louis, MO (2008-2009)
  • Resident Physician, Anatomic and Clinical Pathology: Washington University/Barnes-Jewish Hospital, St. Louis, MO (2004-2008)
  • Medical Degree: University of Tennessee College of Medicine, Memphis, TN (1999-2004)
  • Cum Laude, Majors in Physics and Chemistry: Vanderbilt University, Nashville, TN (1994-1998)
  • Tennessee Honors Diploma: Brentwood High School, Brentwood, TN (1990-1994)

Board Certifications

  • Board Certified in Anatomic and Clinical Pathology
  • Board Certified in Molecular Pathology
  • Board Certified in Hematopathology
  • Board Certified in Clinical Informatics
  • NY State Certificate of Qualification (Histology and Molecular)

Recognition

  • Harry Hill Departmental Research Grant, University of Utah, 2009
  • College of American Pathologists (CAP) Research Training Grant, 2009
  • Pulmonary Pathology Society Trainee Research Award, USCAP 2009
  • American Medical Association Resident Research Grant, 2008
  • CAP Fall Informatics Meeting (APIII) Travel Grant, 2007
  • CAP Spring Informatics Meeting Travel Grant, 2007
  • University of Tennessee Alumni Achievement Research Award, 2004
  • Howard Hughes Medical Institute Predoctoral Fellowship, 2001
  • NIH Summer Medical Student Research, Fellowship Recipient, 2000
  • Honorable Mention–Tennessee Biomedical Research Fair, 1998

Clinical Interests

  • Hematopathology
  • Molecular Genetic Pathology

Research Interests

As a physician-scientist, my time is split between clinical sign out of hematologic biopsies and molecular diagnostic cases as well as the development of new clinical diagnostic methods and understanding the molecular mechanisms of MDS.  My long-term clinical vision is to apply advanced high throughput molecular methods such as whole-genome sequencing and error corrected measurable residual disease sequencing to clinical care in order for clinicians to make better-informed treatment decisions. I have a long-standing interest in sequencing-based cancer diagnostics and developed the first CAP/CLIA accredited NGS-based cancer sequencing assay at an academic laboratory in 2011. Outside of Washington University, I served on the first standards committee to address NGS-based clinical testing (Clinical Laboratory Standards Institute, m09) and co-chaired the AMP/ASCO/CAP guidelines for somatic variant reporting in cancer. As a past K12 award recipient and SPORE career enhancement program awardee, I have spent the last seven years working with established leaders in the field of molecular oncology research including Drs. Matthew Walter and Tim Ley. During this time I developed targeted ultra-sensitive sequencing methods for the detection of low-frequency variants in MDS and AML for measurable residual disease (MRD) applications that now form the basis of our clinical testing at Washington University and were funded in part through an IMAT R33 award. More recently my laboratory has studied the use of whole-genome sequencing to replace conventional cytogenetics in the clinical evaluation of hematologic malignancies.

Selected Publications

Rosenbaum, Jason N; Bloom, Ryan; Forys, Jason T; Hiken, Jeff; Armstrong, Jon R; Branson, Julie; McNulty, Samantha; Velu, Priya D; Pepin, Kymberlie; Abel, Haley; Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer. Modern Pathology. Volume 31, 5; pages 791-808, 2018, Nature Publishing Group.
Duncavage, Eric J; Jacoby, Meagan A; Chang, Gue Su; Miller, Christopher A; Edwin, Natasha; Shao, Jin; Elliott, Kevin; Robinson, Joshua; Abel, Haley; Fulton, Robert S; Mutation clearance after transplantation for myelodysplastic syndrome. New England Journal of Medicine. Volume 379, 11; pages 1028-1041, 2018, Massachusetts Medical Society.
Christopher, Matthew J; Petti, Allegra A; Rettig, Michael P; Miller, Christopher A; Chendamarai, Ezhilarasi; Duncavage, Eric J; Klco, Jeffery M; Helton, Nicole M; O’Laughlin, Michelle; Fronick, Catrina C; Immune escape of relapsed AML cells after allogeneic transplantation. New England Journal of Medicine. Volume 379, 24; pages 2330-2341, 2018, Massachusetts Medical Society.
Li, Marilyn M; Datto, Michael; Duncavage, Eric J; Kulkarni, Shashikant; Lindeman, Neal I; Roy, Somak; Tsimberidou, Apostolia M; Vnencak-Jones, Cindy L; Wolff, Daynna J; Younes, Anas; Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. The Journal of Molecular Diagnostics. Volume 19, 1; 2017. Elsevier
Welch, John S; Petti, Allegra A; Miller, Christopher A; Fronick, Catrina C; O’Laughlin, Michelle; Fulton, Robert S; Wilson, Richard K; Baty, Jack D; Duncavage, Eric J; Tandon, Bevan; TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. New England Journal of Medicine. Volume 375, 21; pages 2023-2036, 2016. Massachusetts Medical Society.
Klco, Jeffery M; Miller, Christopher A; Griffith, Malachi; Petti, Allegra; Spencer, David H; Ketkar-Kulkarni, Shamika; Wartman, Lukas D; Christopher, Matthew; Lamprecht, Tamara L; Helton, Nicole M; Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia. JAMA. Volume 314, 8; pages 811-822, 2015. American Medical Association.
Abel, Haley J; Al-Kateb, Hussam; Cottrell, Catherine E; Bredemeyer, Andrew J; Pritchard, Colin C; Grossmann, Allie H; Wallander, Michelle L; Pfeifer, John D; Lockwood, Christina M; Duncavage, Eric J; Detection of gene rearrangements in targeted clinical next-generation sequencing. The Journal of Molecular Diagnostics. Volume 16, 4; pages 405-417, 2014. Elsevier.
Spencer, David H; Abel, Haley J; Lockwood, Christina M; Payton, Jacqueline E; Szankasi, Philippe; Kelley, Todd W; Kulkarni, Shashikant; Pfeifer, John D; Duncavage, Eric J; Detection of FLT3 internal tandem duplication in targeted, short-read-length, next-generation sequencing data. The Journal of Molecular Diagnostics. Volume 15, 1; pages 81-93, 2013. Elsevier.
Spencer, David H; Sehn, Jennifer K; Abel, Haley J; Watson, Mark A; Pfeifer, John D; Duncavage, Eric J; Comparison of clinical targeted next-generation sequence data from formalin-fixed and fresh-frozen tissue specimens. The Journal of Molecular Diagnostics. Volume 15, 5; pages 623-633, 2013. Elsevier.
Duncavage, Eric J; Abel, Haley J; Szankasi, Philippe; Kelley, Todd W; Pfeifer, John D; Targeted next-generation sequencing of clinically significant gene mutations and translocations in leukemia. Modern Pathology. Volume 25, 6; pages 795-804, 2012. Nature Publishing Group.

Assistant:
Dani Salazar
314-362-2975
sdaniela@wustl.edu